Free tool
FAERS Monitor: Imodium Multi-Symptom Relief
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021140 or its brand name (Imodium Multi-Symptom Relief, Loperamide Hydrochloride, Simethicone). Reports on generic versions are filed under their own applications.
Reports
32,268
Serious
18,867
58% of reports
Hospitalization
11,312
Death reported
2,549
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- diarrhoea6,587
- drug ineffective3,174
- nausea3,134
- fatigue2,654
- off label use2,287
- vomiting2,148
- constipation1,816
- weight decreased1,538
- incorrect dose administered1,429
- headache1,398
- dyspnoea1,388
- abdominal pain1,362
- asthenia1,334
- dehydration1,245
- dizziness1,245
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 255 |
| 2005 | 303 |
| 2006 | 321 |
| 2007 | 354 |
| 2008 | 410 |
| 2009 | 424 |
| 2010 | 473 |
| 2011 | 671 |
| 2012 | 874 |
| 2013 | 770 |
| 2014 | 970 |
| 2015 | 4,439 |
| 2016 | 1,910 |
| 2017 | 2,173 |
| 2018 | 2,311 |
| 2019 | 1,989 |
| 2020 | 2,173 |
| 2021 | 2,035 |
| 2022 | 2,152 |
| 2023 | 2,354 |
| 2024 | 1,928 |
| 2025 | 1,862 |
| 2026 | 1,114 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,021,891 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| diarrhoeaSignal | 6,587 | 6.7 | 6.6 | 32,675 |
| dehydrationSignal | 1,245 | 6.1 | 5.8 | 5,326 |
| constipationSignal | 1,816 | 5.5 | 5.2 | 6,634 |
| incorrect dose administeredSignal | 1,429 | 4.1 | 3.9 | 3,362 |
| abdominal painSignal | 1,362 | 3.8 | 3.6 | 2,864 |
| weight decreasedSignal | 1,538 | 3.6 | 3.4 | 2,916 |
| vomitingSignal | 2,148 | 3.0 | 2.9 | 2,889 |
| nauseaSignal | 3,134 | 2.6 | 2.5 | 3,157 |
| astheniaSignal | 1,334 | 2.3 | 2.2 | 1,012 |
| fatigueSignal | 2,654 | 2.2 | 2.1 | 1,854 |
| off label use | 2,287 | 1.7 | 1.6 | 692 |
| dizziness | 1,245 | 1.6 | 1.5 | 308 |
| dyspnoea | 1,388 | 1.6 | 1.5 | 319 |
| drug ineffective | 3,174 | 1.6 | 1.5 | 701 |
| headache | 1,398 | 1.5 | 1.4 | 204 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.